Neanderthal Protein May Reduce the Severity of COVID-19

Read Time:
Researchers at the Lady Davis Institute (LDI) at the Jewish General Hospital have discovered that increased levels of the protein OAS1 are associated with reduced mortality and less severe disease requiring ventilation among patients with COVID-19. Using drugs that boost OAS1 levels could be explored to try to improve these outcomes. The findings are published today in 
“Our analysis shows evidence that OAS1 has a protective effect against COVID-19 susceptibility and severity,” explains Dr. Brent Richards, a senior investigator at the LDI’s Centre for Clinical Epidemiology and Professor of Medicine, Human Genetics, Epidemiology and Biostatistics at McGill University. “This is a very exciting development in the race to identify potential therapies to treat patients because there are already therapies in pre-clinical development that boost OAS1 and could be explored for their effect against SARS-CoV-2 infection.”

Related Keywords

Sirui Zhou , Brent Richards , Centre For Clinical Epidemiology , Mcgill University , Lady Davis Institute , Jewish General Hospital , Clinical Epidemiology , Human Genetics , ப்ரெண்ட் ரிச்சர்ட்ஸ் , மையம் க்கு மருத்துவ தொற்றுநோய் , மகில் பல்கலைக்கழகம் , பெண் டேவிஸ் நிறுவனம் , நகை ஜநரல் மருத்துவமனை , மருத்துவ தொற்றுநோய் , மனிதன் ஜெநெடிக்ஸ் ,